Endocrine Society GUIDELINES Bundle (free trial)

Testosterone Therapy in Men with Hypogonadism

Endocrine Society GUIDELINES Apps brought to you free of charge courtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/302958

Contents of this Issue

Navigation

Page 4 of 17

5 Table 2. Symptoms and Signs Suggestive of T Deficiency in Men Specific symptoms and signs • Incomplete or delayed sexual development • Loss of body (axillary and pubic) hair • Very small testes (<6 mL) Suggestive symptoms and signs • Reduced sexual desire (libido) and activity • Decreased spontaneous erections, erectile dysfunction • Breast discomfort, g ynecomastia • Eunuchoidal body proportions • Inability to father children, low sperm count • Height loss, low-trauma fracture, low bone mineral density (BMD) • Hot flushes, sweats Nonspecific symptoms and signs associated with T deficiency • Decreased energ y, motivation, initiative, and self-confidence • Feeling sad or blue, depressed mood, persistent low-grade depressive disorder • Poor concentration and memory • Sleep disturbance, increased sleepiness • Mild unexplained anemia (normochromic, normocytic) • Reduced muscle bulk and strength • Increased body fat, body mass index Adapted with permission from Bhasin et al. J Clin Endocrinol Metab. 2010;95(6): 2536–2559. Table 3. Conditions in Which Measurement of FT Concentration is Recommended Conditions that are associated with decreased SHBG concentrations: • Obesity • Diabetes mellitus • Use of glucocorticoids, some progestins, and androgenic steroids • Nephrotic syndrome • Hypothyroidism • Acromegaly • Polymorphisms in the sex hormone- binding globulin (SHBG) gene Conditions associated with increased SHBG concentrations: • Aging • HIV disease • Cirrhosis and hepatitis • Hyperthyroidism • Use of some anticonvulsants • Use of estrogens • Polymorphisms in the SHBG gene Total testosterone concentrations in the borderline zone around the lower limit of the normal range (e.g., 200–400 ng/dL) Adapted with permission from Bhasin et al. Androlog y 2018;6(1):151–157.

Articles in this issue

Archives of this issue

view archives of Endocrine Society GUIDELINES Bundle (free trial) - Testosterone Therapy in Men with Hypogonadism